RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000077.xml
PDF herunterladen
Semin Thromb Hemost 2010; 36(4): 404-418
DOI: 10.1055/s-0030-1254049
© Thieme Medical PublishersDOI: 10.1055/s-0030-1254049
Disseminated Intravascular Coagulation in Obstetric and Gynecologic Disorders
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
07. Juli 2010 (online)
ABSTRACT
Disseminated intravascular coagulation (DIC) is a syndrome characterized by a massive, widespread, and ongoing activation of the coagulation system, secondary to a variety of clinical conditions. Many obstetric complications, such as abruptio placentae, amniotic fluid embolism, endotoxin sepsis, retained dead fetus, post-hemorrhagic shock, hydatidiform mole, and gynecologic malignancies, might trigger DIC. In these gynecologic and obstetric settings, DIC is usually associated with high mortality and morbidity rates. No single laboratory test is sensitive or specific enough to diagnose DIC definitively, but it can be diagnosed by using a combination of multiple clinical and laboratory tests that reflect the pathophysiology of the syndrome. At present, the therapeutical approach to pregnancy- and gynecologic-related DIC comprises the specific and aggressive treatment of the underlying disease, eventually followed by a supportive blood product replacement therapy and restoration of physiological anticoagulant pathways. This article reviews the etiopathogenesis, clinical manifestations, laboratory diagnosis, and therapy of pregnancy- and gynecologic-related DIC.
KEYWORDS
Coagulation - disseminated intravascular coagulation - DIC - obstetrics - pregnancy
REFERENCES
- 1 Matsuda T. Clinical aspects of DIC—disseminated intravascular coagulation. Pol J Pharmacol. 1996; 48(1) 73-75
- 2 Taylor Jr F B, Toh C H, Hoots W K, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH) . Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001; 86(5) 1327-1330
- 3 Levi M. Disseminated intravascular coagulation. Crit Care Med. 2007; 35(9) 2191-2195
- 4 Letsky E A. Disseminated intravascular coagulation. Best Pract Res Clin Obstet Gynaecol. 2001; 15(4) 623-644
- 5 Franchini M, Lippi G, Manzato F. Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thromb J. 2006; 4 4
- 6 Franchini M. Haemostasis and pregnancy. Thromb Haemost. 2006; 95(3) 401-413
- 7 O'Riordan M N, Higgins J R. Haemostasis in normal and abnormal pregnancy. Best Pract Res Clin Obstet Gynaecol. 2003; 17(3) 385-396
- 8 Bremme K A. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol. 2003; 16(2) 153-168
- 9 Sattar N, Greer I A, Rumley A et al.. A longitudinal study of the relationships between haemostatic, lipid, and oestradiol changes during normal human pregnancy. Thromb Haemost. 1999; 81(1) 71-75
- 10 Stirling Y, Woolf L, North W RS, Seghatchian M J, Meade T W. Haemostasis in normal pregnancy. Thromb Haemost. 1984; 52(2) 176-182
- 11 Dalaker K, Prydz H. The coagulation factor VII in pregnancy. Br J Haematol. 1984; 56(2) 233-241
- 12 Østerud B, Bjørklid E. Sources of tissue factor. Semin Thromb Hemost. 2006; 32(1) 11-23
- 13 Cerneca F, Ricci G, Simeone R, Malisano M, Alberico S, Guaschino S. Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur J Obstet Gynecol Reprod Biol. 1997; 73(1) 31-36
- 14 Collen D, de Cock F, Verstraete M. Quantitation of thrombin-antithrombin III complexes in human blood. Eur J Clin Invest. 1977; 7(5) 407-411
- 15 Mahieu B, Jacobs N, Mahieu S et al.. Haemostatic changes and acquired activated protein C resistance in normal pregnancy. Blood Coagul Fibrinolysis. 2007; 18(7) 685-688
- 16 Oruç S, Saruç M, Koyuncu F M, Ozdemir E. Changes in the plasma activities of protein C and protein S during pregnancy. Aust N Z J Obstet Gynaecol. 2000; 40(4) 448-450
- 17 Lindqvist P G, Svensson P J, Marsaál K, Grennert L, Luterkort M, Dahlbäck B. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost. 1999; 81(4) 532-537
- 18 Lindqvist P G, Svensson P, Dahlbäck B. Activated protein C resistance—in the absence of factor V Leiden—and pregnancy. J Thromb Haemost. 2006; 4(2) 361-366
- 19 Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003; 29(2) 125-130
- 20 Robb A O, Mills N L, Din J N et al.. Acute endothelial tissue plasminogen activator release in pregnancy. J Thromb Haemost. 2009; 7(1) 138-142
- 21 Astedt B, Hägerstrand I, Lecander I. Cellular localisation in placenta of placental type plasminogen activator inhibitor. Thromb Haemost. 1986; 56(1) 63-65
- 22 Delorme M A, Burrows R F, Ofosu F A, Andrew M. Thrombin regulation in mother and fetus during pregnancy. Semin Thromb Hemost. 1992; 18(1) 81-90
- 23 Maruyama I, Bell C E, Majerus P W. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. J Cell Biol. 1985; 101(2) 363-371
- 24 Crawley J T, Gu J M, Ferrell G, Esmon C T. Distribution of endothelial cell protein C/activated protein C receptor (EPCR) during mouse embryo development. Thromb Haemost. 2002; 88(2) 259-266
- 25 Edstrom C S, Calhoun D A, Christensen R D. Expression of tissue factor pathway inhibitor in human fetal and placental tissues. Early Hum Dev. 2000; 59(2) 77-84
- 26 Liu X H, Jiang Y M, Shi H, Yue X A, Wang Y F, Yang H. Prospective, sequential, longitudinal study of coagulation changes during pregnancy in Chinese women. Int J Gynaecol Obstet. 2009; 105(3) 240-243
- 27 Fay R A, Hughes A O, Farron N T. Platelets in pregnancy: hyperdestruction in pregnancy. Obstet Gynecol. 1983; 61(2) 238-240
- 28 Justin C, Taylor D J.
Bleeding in late pregnancy . In: James DK, Steer PJ, Weiner CP, Gonik B High Risk Pregnancy. 2nd ed. Philadelphia, PA; WB Saunders 1999: 111-128 - 29 Sher G, Statland B E. Abruptio placentae with coagulopathy: a rational basis for management. Clin Obstet Gynecol. 1985; 28(1) 15-23
- 30 Hall D R. Abruptio placentae and disseminated intravascular coagulopathy. Semin Perinatol. 2009; 33(3) 189-195
- 31 Krikun G, Huang S T, Schatz F, Salafia C, Stocco C, Lockwood C J. Thrombin activation of endometrial endothelial cells: a possible role in intrauterine growth restriction. Thromb Haemost. 2007; 97(2) 245-253
- 32 Kuczyński J, Uszyński W, Zekanowska E, Soszka T, Uszyński M. Tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in the placenta and myometrium. Eur J Obstet Gynecol Reprod Biol. 2002; 105(1) 15-19
- 33 Mahmoodian S. DIC and acute renal failure as a complication of abruptio placentae. W V Med J. 1989; 85(12) 527-530
- 34 Lain K Y, Roberts J M. Contemporary concepts of the pathogenesis and management of preeclampsia. JAMA. 2002; 287(24) 3183-3186
- 35 Practice Bulletin ACOG .Diagnosis and Management of Preeclampsia and Eclampsia. Clinical Management Guidelines for Obstetrician-Gynecologists. Washington, DC; American College of Obstetricians and Gynecologists 2002 Number 33
- 36 Rath W, Faridi A, Dudenhausen J W. HELLP syndrome. J Perinat Med. 2000; 28(4) 249-260
- 37 Sibai B M. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 2004; 103(5 Pt 1) 981-991
- 38 Roberts J M, Lain K Y. Recent Insights into the pathogenesis of pre-eclampsia. Placenta. 2002; 23(5) 359-372
- 39 Rinehart B K, Terrone D A, Lagoo-Deenadayalan S et al.. Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin 10 is increased in preeclampsia. Am J Obstet Gynecol. 1999; 181(4) 915-920
- 40 Tanjung M T, Siddik H D, Hariman H, Koh S C. Coagulation and fibrinolysis in preeclampsia and neonates. Clin Appl Thromb Hemost. 2005; 11(4) 467-473
- 41 Popek E J.
Normal anatomy and histology of the placenta . In: Lewis SH, Perrin EZ Pathology of the Placenta. 2nd ed. Philadelphia, PA; Churchill Livingstone 1999: 49-88 - 42 Griffin J H, Kojima K, Banka C L, Curtiss L K, Fernández J A. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest. 1999; 103(2) 219-227
- 43 Thachil J, Toh C H. Disseminated intravascular coagulation in obstetric disorders and its acute haematological management. Blood Rev. 2009; 23(4) 167-176
- 44 van der Poll T, Büller H R, ten Cate H et al.. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med. 1990; 322(23) 1622-1627
- 45 Coughlin S R. Thrombin signalling and protease-activated receptors. Nature. 2000; 407(6801) 258-264
- 46 Schjetlein R, Haugen G, Wisløff F. Markers of intravascular coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation. Acta Obstet Gynecol Scand. 1997; 76(6) 541-546
- 47 Perry Jr K G, Martin Jr J N. Abnormal hemostasis and coagulopathy in preeclampsia and eclampsia. Clin Obstet Gynecol. 1992; 35(2) 338-350
- 48 Narumiya H, Zhang Y, Fernandez-Patron C, Guilbert L J, Davidge S T. Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia. Hypertens Pregnancy. 2001; 20(2) 185-194
- 49 Clark S L, Hankins G DV, Dudley D A, Dildy G A, Porter T F. Amniotic fluid embolism: analysis of the national registry. Am J Obstet Gynecol. 1995; 172(4 Pt 1) 1158-1167 discussion 1167-1169
- 50 Perozzi K J, Englert N C. Amniotic fluid embolism: an obstetric emergency. Crit Care Nurse. 2004; 24(4) 54-61
- 51 Phillips L L, Davidson Jr E C. Procoagulant properties of amniotic fluid. Am J Obstet Gynecol. 1972; 113(7) 911-919
- 52 Zhou J, Liu S, Ma M et al.. Procoagulant activity and phosphatidylserine of amniotic fluid cells. Thromb Haemost. 2009; 101(5) 845-851
- 53 Uszynski M. Amniotic fluid embolism: the complication of known pathomechanism but without pathogenetic therapy?. Thromb Haemost. 2009; 101(5) 795-796
- 54 Butler E E, Colón I, Druzin M L, Rose J. Postural equilibrium during pregnancy: decreased stability with an increased reliance on visual cues. Am J Obstet Gynecol. 2006; 195(4) 1104-1108
- 55 Yaffe H, Hay-Am E, Sadovsky E. Thromboplastic activity of amniotic fluid in term and postmature gestations. Obstet Gynecol. 1981; 57(4) 490-492
- 56 Benson M D. A hypothesis regarding complement activation and amniotic fluid embolism. Med Hypotheses. 2007; 68(5) 1019-1025
- 57 Gómez Ponce de León R, Wing D, Fiala C. Misoprostol for intrauterine fetal death. Int J Gynaecol Obstet. 2007; 99(Suppl 2) S190-S193
- 58 Pollak L, Schiffer J, Leonov Y, Zaidenstein R. Acute subdural hematoma following disseminated intravascular coagulation associated with an obstetric catastrophe. Isr J Med Sci. 1995; 31(8) 489-491
- 59 Erez O, Gotsch F, Mazaki-Tovi S et al.. Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death. J Matern Fetal Neonatal Med. 2009; 22(8) 672-687
- 60 van Gorp E C, Suharti C, ten Cate H et al.. Review: infectious diseases and coagulation disorders. J Infect Dis. 1999; 180(1) 176-186
- 61 Rana A, Pradhan N, Gurung G, Singh M. Induced septic abortion: a major factor in maternal mortality and morbidity. J Obstet Gynaecol Res. 2004; 30(1) 3-8
- 62 Thorp J A, Helfgott A W, King E A, King A A, Minyard A N. Maternal death after second-trimester genetic amniocentesis. Obstet Gynecol. 2005; 105(5 Pt 2) 1213-1215
- 63 Hamoda H, Chamberlain P F. Clostridium welchii infection following amniocentesis: a case report and review of the literature. Prenat Diagn. 2002; 22(9) 783-785
- 64 Plachouras N, Sotiriadis A, Dalkalitsis N, Kontostolis E, Xiropotamos N, Paraskevaidis E. Fulminant sepsis after invasive prenatal diagnosis. Obstet Gynecol. 2004; 104(6) 1244-1247
- 65 Barela A I, Kleinman G E, Golditch I M, Menke D J, Hogge W A, Golbus M S. Septic shock with renal failure after chorionic villus sampling. Am J Obstet Gynecol. 1986; 154(5) 1100-1102
- 66 Rittirsch D, Flierl M A, Ward P A. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008; 8(10) 776-787
- 67 Schouten M, Wiersinga W J, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol. 2008; 83(3) 536-545
- 68 Okajima K, Uchiba M, Murakami K, Okabe H, Takatsuki K. Plasma levels of soluble E-selectin in patients with disseminated intravascular coagulation. Am J Hematol. 1997; 54(3) 219-224
- 69 Hack C E. Fibrinolysis in disseminated intravascular coagulation. Semin Thromb Hemost. 2001; 27(6) 633-638
- 70 Bick R L. Disseminated intravascular coagulation: a review of etiology, pathophysiology, diagnosis, and management: guidelines for care. Clin Appl Thromb Hemost. 2002; 8(1) 1-31
- 71 Hofmeyr G J, Mohlala B K. Hypovolaemic shock. Best Pract Res Clin Obstet Gynaecol. 2001; 15 645-662
- 72 Purdie F R, Nieto J M, Summerson D J, Livermore W E. Rupture of the uterus with DIC. Ann Emerg Med. 1983; 12(3) 174-176
- 73 Zimmerman L H. Causes and consequences of critical bleeding and mechanisms of blood coagulation. Pharmacotherapy. 2007; 27(9 Pt 2) 45S-56S
- 74 Drife J. Management of primary postpartum haemorrhage. Br J Obstet Gynaecol. 1997; 104(3) 275-277
- 75 Haljamäe H. The pathophysiology of shock. Acta Anaesthesiol Scand Suppl. 1993; 98 3-6
- 76 Sherman L A. DIC in massive transfusion. Prog Clin Biol Res. 1982; 108 171-189
- 77 Linder M, Müller-Berghaus G, Lasch H G, Gagel C. Virus infection and blood coagulation. Thromb Diath Haemorrh. 1970; 23(1) 1-11
- 78 McKay D G, Margaretten W. Disseminated intravascular coagulation in virus diseases. Arch Intern Med. 1967; 120(2) 129-152
- 79 Yücesoy G, Ozkan S O, Bodur H, Cakiroğlu Y, Calişkan E, Ozeren S. Acute fatty liver of pregnancy complicated with disseminated intravascular coagulation and haemorrhage: a case report. Int J Clin Pract Suppl. 2005; 147(Suppl) 82-84
- 80 Bick R L. Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Semin Thromb Hemost. 1978; 5(1) 1-26
- 81 Contrino J, Hair G, Kreutzer D L, Rickles F R. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med. 1996; 2(2) 209-215
- 82 Falanga A, Rickles F R. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost. 1999; 25(2) 173-182
- 83 Falanga A, Consonni R, Marchetti M et al.. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood. 1998; 92 143-151
- 84 Donati M B. Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. Thromb Haemost. 1995; 74(1) 278-281
- 85 Semeraro N, Montemurro P, Conese M et al.. Procoagulant activity of mononuclear phagocytes from different anatomical sites in patients with gynecological malignancies. Int J Cancer. 1990; 45(2) 251-254
- 86 Levi M. Disseminated intravascular coagulation in cancer patients. Best Pract Res Clin Haematol. 2009; 22(1) 129-136
- 87 Rickles F R, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res. 2001; 102(6) V215-V224
- 88 Tsakok F H, Koh S, Ilancheran A, Poh W K, Ratnam S S. Maternal death associated with hydatidiform molar pregnancy. Int J Gynaecol Obstet. 1983; 21(6) 485-490
- 89 Egley C C, Simon L R, Haddox T. Hydatidiform mole and disseminated intravascular coagulation. Am J Obstet Gynecol. 1975; 121(8) 1122
- 90 Levi M, Toh C H, Thachil J, Watson H G. British Committee for Standards in Haematology . Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol. 2009; 145(1) 24-33
- 91 Mant M J, King E G. Severe, acute disseminated intravascular coagulation. A reappraisal of its pathophysiology, clinical significance and therapy based on 47 patients. Am J Med. 1979; 67(4) 557-563
- 92 Mant M J, Hirsh J, Pineo G F, Luke K H. Prolonged prothrombin time and partial thromboplastin time in disseminated intravascular coagulation not due to deficiency of factors V and VIII. Br J Haematol. 1973; 24(6) 725-734
- 93 Deutsch H F, Gerarde H W. Biophysical studies of blood plasma proteins: effect of fibrinogen on prothrombin time. J Biol Chem. 1946; 166 381
- 94 Pati H P, Saraya A K, Charan V D, Sundaram K R, Sharma M C, Choudhary V P. Prognostic role of screening tests of haemostasis and underlying diseases in acute disseminated intra-vascular coagulation in adults. Clin Lab Haematol. 1994; 16(1) 9-13
- 95 Bick R L. Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response. Semin Thromb Hemost. 1996; 22(1) 69-88
- 96 Toh C H, Dennis M. Disseminated intravascular coagulation: old disease, new hope. BMJ. 2003; 327(7421) 974-977
- 97 Lippi G, Favaloro E J. Activated partial thromboplastin time: new tricks for an old dogma. Semin Thromb Hemost. 2008; 34(7) 604-611
- 98 Toh C H, Giles A R. Waveform analysis of clotting test optical profiles in the diagnosis and management of disseminated intravascular coagulation (DIC). Clin Lab Haematol. 2002; 24(6) 321-327
- 99 Bick R L. Disseminated intravascular coagulation: clinical/laboratory correlations. Am J Clin Pathol. 1982; 77 244
- 100 Ten Cate H. Trombocytopenia: one of the markers of disseminated intravascular coagulation. Pathophysiol Haemost Thromb. 2003–2004; 33(5–6) 413-416
- 101 Spero J A, Lewis J H, Hasiba U. Disseminated intravascular coagulation. Findings in 346 patients. Thromb Haemost. 1980; 43(1) 28-33
- 102 Drews R E. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients. Clin Chest Med. 2003; 24(4) 607-622
- 103 Hong K H, Kim H K, Kim J E, Jung J S, Han K S, Cho H I. Prognostic value of immature platelet fraction and plasma thrombopoietin in disseminated intravascular coagulation. Blood Coagul Fibrinolysis. 2009; 20(6) 409-414
- 104 Kim H K, Kim J E, Ham C K, Lee D S, Park S, Cho H I. Prognostic value of platelet indices as determined by ADVIA 120 in patients suspected of having disseminated intravascular coagulation. Int J Lab Hematol. 2008; 30(2) 117-123
- 105 Labelle C A, Kitchens C S. Disseminated intravascular coagulation: treat the cause, not the lab values. Cleve Clin J Med. 2005; 72(5) 377-378, 383–385, 390 passim
- 106 Kim H K, Lee D S, Kang S H, Kim J Q, Park S, Cho H I. Utility of the fibrinogen/C-reactive protein ratio for the diagnosis of disseminated intravascular coagulation. Acta Haematol. 2007; 117(1) 34-39
- 107 Asakura H, Shiratori Y, Jokaji H et al.. Changes in plasma levels of prothrombin fragment F 1 + 2 in cases of disseminated intravascular coagulation. Acta Haematol. 1993; 89(1) 22-25
- 108 Takahashi H, Wada K, Niwano H, Shibata A. Comparison of prothrombin fragment 1 + 2 with thrombin-antithrombin III complex in plasma of patients with disseminated intravascular coagulation. Blood Coagul Fibrinolysis. 1992; 3(6) 813-818
- 109 Teitel J M, Bauer K A, Lau H K, Rosenberg R D. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin-antithrombin complex. Blood. 1982; 59(5) 1086-1097
- 110 Bick R L. Disseminated intravascular coagulation current concepts of etiology, pathophysiology, diagnosis, and treatment. Hematol Oncol Clin North Am. 2003; 17(1) 149-176
- 111 Rosenberg J S, Beeler D L, Rosenberg R D. Activation of human prothrombin by highly purified human factors V and X-a in presence of human antithrombin. J Biol Chem. 1975; 250(5) 1607-1617
- 112 Wada H, Minamikawa K, Wakita Y et al.. Hemostatic study before onset of disseminated intravascular coagulation. Am J Hematol. 1993; 43 190-194
- 113 Okugawa Y, Wada H, Noda T et al.. Increased plasma levels of tissue factor pathway inhibitor-activated factor X complex in patients with disseminated intravascular coagulation. Am J Hematol. 2000; 65(3) 210-214
- 114 Kawasugi K, Simazu C, Noguchi M et al.. Increased thrombin generation capacity in septic patients with DIC. J Thromb Haemost. 2007; 5(Suppl 2) P-T-236
- 115 Hemker H C, Al Dieri R, De Smedt E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006; 96(5) 553-561
- 116 Seo J W, Kim H K, Kim J E, Park S, Cho H I. Prognostic values of the factor Xa-activated clotting time and endogenous thrombin potential in patients suspected of having disseminated intravascular coagulation. Thromb Res. 2009; 123(4) 565-572
- 117 Exner T, Joseph J, Low J, Connor D, Ma D. A new activated factor X-based clotting method with improved specificity for procoagulant phospholipid. Blood Coagul Fibrinolysis. 2003; 14(8) 773-779
- 118 Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999; 341(8) 586-592
- 119 Cadroy Y, Grandjean H, Pichon J et al.. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Obstet Gynaecol. 1993; 100(5) 416-420
- 120 Takahashi H, Hanano M, Takizawa S, Tatewaki W, Shibata A. Plasmin-alpha 2-plasmin inhibitor complex in plasma of patients with disseminated intravascular coagulation. Am J Hematol. 1988; 28(3) 162-166
- 121 Shaper A G, Macintosh D M, Evans C M, Kyobe J. Fibrinolysis and plasminogen levels in pregnancy and the puerperium. Lancet. 1965; 2(7415) 706-708
- 122 Kruithof E K, Tran-Thang C, Gudinchet A et al.. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood. 1987; 69(2) 460-466
- 123 Carr J M, McKinney M, McDonagh J. Diagnosis of disseminated intravascular coagulation. Role of D-dimer. Am J Clin Pathol. 1989; 91(3) 280-287
- 124 Brenner B. Haemostatic changes in pregnancy. Thromb Res. 2004; 114(5–6) 409-414
- 125 Francis C W, Marder V J. A molecular model of plasmic degradation of crosslinked fibrin. Semin Thromb Hemost. 1982; 8(1) 25-35
- 126 Bick R L, Baker W F. Diagnostic efficacy of the D-dimer assay in disseminated intravascular coagulation (DIC). Thromb Res. 1992; 65 785-790
- 127 Toh C H, Hoots W K. SSC on Disseminated Intravascular Coagulation of the ISTH . The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J Thromb Haemost. 2007; 5(3) 604-606
- 128 Nakahara K, Kazahaya Y, Shintani Y et al.. Measurement of soluble fibrin monomer-fibrinogen complex in plasmas derived from patients with various underlying clinical situations. Thromb Haemost. 2003; 89(5) 832-836
- 129 Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost. 2008; 34(5) 459-468
- 130 Levi M. Disseminated intravascular coagulation: what's new?. Crit Care Clin. 2005; 21(3) 449-467
- 131 Esmon C T. The regulation of natural anticoagulant pathways. Science. 1987; 235(4794) 1348-1352
- 132 Clark P, Brennand J, Conkie J A, McCall F, Greer I A, Walker I D. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost. 1998; 79(6) 1166-1170
- 133 Bick R L, Dukes M L, Wilson W L, Fekete L F. Antithrombin III(AT-III) as a diagnostic aid in disseminated intravascular coagulation. Thromb Res. 1977; 10(5) 721-729
- 134 Holmes W E, Nelles L, Lijnen H R, Collen D. Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin). J Biol Chem. 1987; 262(4) 1659-1664
- 135 Harpel P C. Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay. J Clin Invest. 1981; 68(1) 46-55
- 136 Levi M, Roem D, Kamp A M, de Boer J P, Hack C E, ten Cate J W. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb Haemost. 1993; 69(2) 141-146
- 137 Mosad E, Elsayh K I, Eltayeb A A. Tissue factor pathway inhibitor and P-selectin as markers of sepsis-induced non-overt disseminated intravascular coagulopathy. Clin Appl Thromb Hemost. 2009; , August 18 (Epub ahead of print)
- 138 Wada H, Gabazza E C, Asakura H et al.. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis and of the Japanese Ministry of Health and Welfare for overt DIC. Am J Hematol. 2003; 74(1) 17-22
- 139 Lippi G, Guidi G C. Laboratory diagnostics in septic disseminated intravascular coagulation. Eur Haematol. 2009; 3 19-24
- 140 Bakhtiari K, Meijers J C, de Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med. 2004; 32(12) 2416-2421
- 141 Gando S, Iba T, Eguchi Y Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006; 34(3) 625-631
- 142 Moore J, Baldisseri M R. Amniotic fluid embolism. Crit Care Med. 2005; 33(10, Suppl) S279-S285
- 143 Williams J, Mozurkewich E, Chilimigras J, Van De Ven C. Critical care in obstetrics: pregnancy-specific conditions. Best Pract Res Clin Obstet Gynaecol. 2008; 22 825-846
- 144 von Dadelszen P, Menzies J, Gilgoff S et al.. Evidence-based management for preeclampsia. Front Biosci. 2007; 12 2876-2889
- 145 Sibai B M. Magnesium sulfate prophylaxis in preeclampsia: evidence from randomized trials. Clin Obstet Gynecol. 2005; 48(2) 478-488
- 146 Magann E F, Martin Jr J N. Twelve steps to optimal management of HELLP syndrome. Clin Obstet Gynecol. 1999; 42(3) 532-550
- 147 Martin Jr J N, Rose C H, Briery C M. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol. 2006; 195(4) 914-934
- 148 Fonseca J E, Méndez F, Cataño C, Arias F. Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol. 2005; 193(5) 1591-1598
- 149 Levi M. Current understanding of disseminated intravascular coagulation. Br J Haematol. 2004; 124(5) 567-576
- 150 Carey M J, Rodgers G M. Disseminated intravascular coagulation: clinical and laboratory aspects. Am J Hematol. 1998; 59(1) 65-73
- 151 Calder L, Hébert P C, Carter A O, Graham I D. Review of published recommendations and guidelines for the transfusion of allogeneic red blood cells and plasma. Can Med Assoc J. 1997; 156(Suppl) S1-S8
- 152 O'shaughnessy D F, Atterbury C, Bolton Maggs P British Committee for Standards in Haematology, Blood Transfusion Task Force et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004; 126(1) 11-28
- 153 Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists. JAMA. 1994; 271(10) 777-781
- 154 Chowdhury P, Saayman A G, Paulus U, Findlay G P, Collins P W. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol. 2004; 125(1) 69-73
- 155 Samama C M. Prothrombin complex concentrates: a brief review. Eur J Anaesthesiol. 2008; 25(10) 784-789
- 156 Josić D, Hoffer L, Buchacher A et al.. Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity. Thromb Res. 2000; 100(5) 433-441
- 157 United Kingdom Haemophilia Centre Doctors' Organisation . Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia. 2003; 9 1-23
- 158 Weinkove R, Rangarajan S. Fibrinogen concentrate for acquired hypofibrinogenaemic states. Transfus Med. 2008; 18(3) 151-157
- 159 Fenger-Eriksen C, Lindberg-Larsen M, Christensen A Q, Ingerslev J, Sørensen B. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth. 2008; 101(6) 769-773
- 160 Kreuz W, Meili E, Peter-Salonen K et al.. Efficacy and tolerability of a pasteurized human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfus Apheresis Sci. 2005; 32 247-253
- 161 Manco-Johnson M J, Dimichele D, Castaman G Fibrinogen Concentrate Study group et al. Pharmacokinetics and safety of fibrinogen concentrate. J Thromb Haemost. 2009; 7(12) 2064-2069
- 162 Pernerstorfer T, Hollenstein U, Hansen J et al.. Heparin blunts endotoxin-induced coagulation activation. Circulation. 1999; 100(25) 2485-2490
- 163 Feinstein D I. Treatment of disseminated intravascular coagulation. Semin Thromb Hemost. 1988; 14(4) 351-362
- 164 Feinstein D I. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood. 1982; 60(2) 284-287
- 165 Howie P W, Prentice C R, Forbes C D. Failure of heparin therapy to affect the clinical course of severe pre-eclampsia. Br J Obstet Gynaecol. 1975; 82(9) 711-717
- 166 Goldhaber S Z. Venous thromboembolism in the intensive care unit: the last frontier for prophylaxis. Chest. 1998; 113(1) 5-7
- 167 Patel R, Cook D J, Meade M O Burden of Illness in venous ThromboEmbolism in Critical care (BITEC) Study Investigators et al. Burden of illness in venous thromboembolism in critical care: a multicenter observational study. J Crit Care. 2005; 20(4) 341-347
- 168 Dörffler-Melly J, de Jonge E, Pont A C et al.. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet. 2002; 359(9309) 849-850
- 169 Rey E, Garneau P, David M et al.. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost. 2009; 7(1) 58-64
- 170 Okabayashi K, Wada H, Ohta S, Shiku H, Nobori T, Maruyama K. Hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit. Am J Hematol. 2004; 76(3) 225-229
- 171 Paternoster D, Stella A, Simioni P, Trovò S, Plebani P, Girolami A. Clotting inhibitors and fibronectin as potential markers in preeclampsia. Int J Gynaecol Obstet. 1994; 47(3) 215-221
- 172 He S, Bremme K, Blombäck M. Acquired deficiency of antithrombin in association with a hypercoagulable state and impaired function of liver and/or kidney in preeclampsia. Blood Coagul Fibrinolysis. 1997; 8(4) 232-238
- 173 Kobayashi A, Matsuda Y, Mitani M, Makino Y, Ohta H. Assessment of the usefulness of antithrombin-III in the management of disseminated intravascular coagulation in obstetrically ill patients. Clin Appl Thromb Hemost. 2009; , October 14 (Epub ahead of print)
- 174 Sameshima H, Kodama Y, Ikenoue T, Kajiwara Y. Antithrombin improves fetal condition in women with severe pre-eclampsia before 32 weeks of gestation; a randomized, double-blind, placebo-controlled trial. J Obstet Gynaecol Res. 2008; 34(1) 34-39
- 175 Kobayashi T, Terao T, Ikenoue T et al.. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Semin Thromb Hemost. 2003; 29(6) 645-652
- 176 Maki M, Kobayashi T, Terao T et al.. Antithrombin therapy for severe preeclampsia. Thromb Haemost. 2000; 84 583-590
- 177 Bernard G R, Vincent J L, Laterre P F Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344(10) 699-709
- 178 Dhainaut J F, Yan S B, Joyce D E et al.. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004; 2(11) 1924-1933
- 179 Bernard G R, Ely E W, Wright T J et al.. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med. 2001; 29(11) 2051-2059
- 180 Kobayashi T, Terao T, Maki M, Ikenoue T. Activated protein C is effective for disseminated intravascular coagulation associated with placental abruption. Thromb Haemost. 1999; 82(4) 1363
- 181 Sobieszczyk S, Breborowicz G, Platicanov V, Tanchev S, Kessler C M. Recombinant factor VIIa in the management of postpartum bleeds: an audit of clinical use. Acta Obstet Gynecol Scand. 2006; 85 1239-1247
- 182 Segal S, Shemesh I Y, Blumental R et al.. The use of recombinant factor VIIa in severe postpartum hemorrhage. Acta Obstet Gynecol Scand. 2004; 83(8) 771-772
- 183 Brice A, Hilbert U, Roger-Christoph S et al.. Recombinant activated factor VII as a life-saving therapy for severe postpartum haemorrhage unresponsive to conservative traditional management. [in French]. Ann Fr Anesth Reanim. 2004; 23(11) 1084-1088
- 184 Ahonen J, Jokela R. Recombinant factor VIIa for life-threatening post-partum haemorrhage. Br J Anaesth. 2005; 94(5) 592-595
- 185 Lewis N R, Brunker P, Lemire S J, Kaufman R M. Failure of recombinant factor VIIa to correct the coagulopathy in a case of severe postpartum hemorrhage. Transfusion. 2009; 49(4) 689-695
- 186 Padmanabhan A, Schwartz J, Spitalnik S L. Transfusion therapy in postpartum hemorrhage. Semin Perinatol. 2009; 33(2) 124-127
- 187 Clark A D, Gordon W C, Walker I D, Tait R C. ‘Last-ditch’ use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang. 2004; 86(2) 120-124
- 188 Franchini M, Franchi M, Bergamini V, Salvagno G L, Montagnana M, Lippi G. A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage. Semin Thromb Hemost. 2008; 34(1) 104-112
- 189 Franchini M, Manzato F, Salvagno G L, Lippi G. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review. Blood Coagul Fibrinolysis. 2007; 18(7) 589-593
- 190 Welsh A, McLintock C, Gatt S, Somerset D, Popham P, Ogle R. Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage. Aust N Z J Obstet Gynaecol. 2008; 48(1) 12-16
Dr. Martina MontagnanaM.D.
Sezione di Chimica Clinica Università degli Studi di Verona, Ospedale Policlinico
G.B. Rossi
P.le Scuro 10, 37134 – Verona, Italy
eMail: martina.montagnana@med.lu.se